Trial Profile
Contrast Enhanced Breast MRI: Comparison of Two Macrocyclic Gadolinium-Based Contrast Agents: Gadoterate Meglumine (Dotarem) and Gadobutrol (Gadavist). A Prospective Study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2023
Price :
$35
*
At a glance
- Drugs Gadobutrol (Primary) ; Gadoterate-meglumine
- Indications Breast disorders
- Focus Diagnostic use
- 05 May 2023 Planned End Date changed from 28 Feb 2024 to 1 Mar 2025.
- 05 May 2023 Planned primary completion date changed from 28 Feb 2023 to 1 Mar 2024.
- 28 Dec 2022 Status changed from suspended to recruiting.